

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines
CURATIVE BIOTECHNOLOGY, INC.

561-907-8990
curativebiotech.com
ir@curativebiotech.com
SIC – 8731/8733

Annual Report
For the Period Ending: December 30, 2022
(the “Reporting Period”)

As of December 30, 2022, the number of shares outstanding of our Common Stock was:

579,271,135

As of September 30, 2022, the number of shares outstanding of our Common Stock was:

571,651,636

As of December 31, 2021, the number of shares outstanding of our Common Stock was:

570,651,636

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

¹ “Change in Control” shall mean any events resulting in:

(i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Curative Biotechnology, Inc., herein referred to as "CUBT" or the "Company."

The company was formerly known as: Connectyx Technologies Holdings Group, Inc., until April 2021, Storage Innovation Technologies, Inc. until 10-07; National Boston Medical, Inc. until 5-04; Fragrance Express, Inc. until 10-98; Growth Industries, Inc. until 7-98

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The Company was originally incorporated on June 29, 1995, in the State of Nevada; the Company, as of October 31, 2007, was reincorporated in the State of Florida and is active in Florida.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address of the issuer's principal executive office:

1825 NW Corporate Blvd., Suite 110
Boca Raton, FL 33431

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

N/A

2) Security Information

Trading symbol: CUBT
Exact title and class of securities outstanding: Common Stock
CUSIP: 23128N108
Par or stated value: \$0.0001

Total shares authorized: 1,100,000,000 as of date: 12/30/2022
Total shares outstanding: 579,271,135 as of date: 12/30/2022
Number of shares in the Public Float²: 252,705,181 as of date: 12/30/2022
Total number of shareholders of record: 215 as of date: 12/30/2022

All additional class(es) of publicly traded securities (if any): *N/A*

Trading symbol: _____
Exact title and class of securities outstanding: _____
CUSIP: _____
Par or stated value: _____
Total shares authorized: _____ as of date: _____
Total shares outstanding: _____ as of date: _____

Transfer Agent

Name: Issuer Direct Corporation
Address: One Glenwood Ave, Suite 1001
Address 2: Raleigh, NC 27603
Phone: +1 (919) 481-4000
Email: info@issuerdirect.com

Is the Transfer Agent registered under the Exchange Act?³ Yes: No:

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Shares Outstanding as of Second Most Recent Fiscal Year End:

Opening Balance

Date 12/31/19 Common: 322,800,327
 Series A Preferred: 34,109,750
 Series B Preferred: 293,000

*Right-click the rows below and select "Insert" to add rows as needed.

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>3/5/20</u>	<u>New Issuance</u>	<u>1,500,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	David Alfred Karram and Sarah Margaret Karram	<u>Web Design and Hosting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>4/28/20</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.0016</u>	<u>No</u>	Pamela Bisikirski and John Bisikirski	<u>Marketing</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/8/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	Ronald W. Bordens, Ph.D.	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/8/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	Michael J. Grace, Ph.D.	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/18/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	I Richard Garr, JD	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>10/8/20</u>	<u>New Issuance</u>	<u>7,000,000</u>	<u>Common</u>	<u>.013</u>	<u>No</u>	Mid Atlantic BioTherapeutics / David Horn, MD	<u>License Execution</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/8/20</u>	<u>New Issuance</u>	<u>100,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Michael K. Fish	<u>Board Fee</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Series A Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Dr. Barry A. Ginsberg	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Series A Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Paul M. Michaels	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>6,000,000</u>	<u>Series C Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Ronald W. Bordens, Ph.D.	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>6,000,000</u>	<u>Series C Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Michael J. Grace, Ph.D.	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>6,000,000</u>	<u>Series C Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	I Richard Garr, JD	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>6,000,000</u>	<u>Series C Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Dr. Barry A. Ginsberg	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>6,000,000</u>	<u>Series C Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Paul M. Michaels	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/3/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Ivel Realty Associates Corp / Marc Lewis	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>

<u>12/9/20</u>	<u>New Issuance</u>	<u>40,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Zabrina Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/9/20</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Theodore Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/9/20</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Samuel Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>01/29/21</u>	<u>New Issuance</u>	<u>27,066,666</u>	<u>Common</u>	<u>.0075</u>	<u>No</u>	Green Life, Inc. (Barry A. Ginsberg)	<u>Conversion of Series B Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>1/29/201</u>	<u>Cancelation</u>	<u>203,000</u>	<u>Series B Preferred</u>	<u>N/A</u>	<u>N/A</u>	Green Life, Inc. (Barry A. Ginsberg)			
<u>02/17/21</u>	<u>New Issuance</u>	<u>5,000,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>40,000</u>	<u>Common</u>	<u>.044</u>	<u>No</u>	Zabrina Langer	<u>Consulting</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Theodore Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.044</u>	<u>No</u>	Theodore Langer	<u>Consulting</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>200,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Samuel Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.044</u>	<u>No</u>	Samuel Langer	<u>Consulting</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>300,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Aaron Charapp	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Ivel Realty Associates (Marc Lewis)	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>6,500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant Exchange Agreement</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,000,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Peter and Gail Capuano	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Charles K McHenry	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Josh York	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Joseph Gantz	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>100,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	John Acito	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>300,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Timothy Sellew	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>

<u>03/12/21</u>	<u>New Issuance</u>	<u>100.000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	SJ Stile Associates, Ltd(Milton Heid)	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,041.667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Rochelle Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,041.667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Rochelle Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,041.667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Theodore Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>2,083.333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Peter and Gail Capuano	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>520.833</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	GG Capital, LLC/(Joseph Gantz)	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>416.667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Samuel Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>208.333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	John Acito	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>625.000</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Aaron Charapp	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>625.000</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Timothy Sellew	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>208.333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Stile Associates Ltd (Milton Heid)	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>520.833</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Josh York	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>520.833</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Charles McHenry	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/17/21</u>	<u>New Issuance</u>	<u>400.000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Max McKenna	<u>Website Development</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/25/21</u>	<u>New Issuance</u>	<u>1,000.000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Jose Bardelas	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/26/21</u>	<u>New Issuance</u>	<u>2,083.333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Jose Bardelas	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>2,921.844</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Jeff Frankel	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>3,565.437</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	William Carlson	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>50,643.813</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Barry A. Ginsberg	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>50,643.813</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Paul Michaels	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>21,931.765</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	SunMed Advisors, LLC (Barry A. Ginsberg) (Paul Michaels)	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>

<u>03/30/21</u>	<u>New Issuance</u>	<u>3,646,396</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Al Forcella	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>645,767</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Amanda Schuman	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>293,734</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	David Evrard	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>391,983</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Gary Kabinoff	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>645,709</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Steven Landau	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>253,219</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	MDM Management Corp II (Michael McMeans)	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>253,219</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Andrew L Phinney	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>Cancelation</u>	<u>134,109.750</u>	<u>Series A Preferred</u>	<u>N/A</u>	<u>N/A</u>	All Series A Holders	<u>Conversion to Common</u>	<u>N/A</u>	<u>N/A</u>
<u>05/12/2021</u>	<u>New Issuance</u>	<u>250.000</u>	<u>Common</u>	<u>.02</u>	<u>No</u>	Dimitar Dimitrov	<u>Scientific Advisory Board fee</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>6/10/2021</u>	<u>New Issuance</u>	<u>10,000.000</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Rochelle Langer	<u>Subscription Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>6/30/2021</u>	<u>New Issuance</u>	<u>840.000</u>	<u>Common</u>	<u>.10</u>	<u>No</u>	Margaret McElroy	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>6/30/2021</u>	<u>New Issuance</u>	<u>1,000.000</u>	<u>Common</u>	<u>.01</u>	<u>Yes</u>	Adam Drimer	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>7/9/2021</u>	<u>New Issuance</u>	<u>1,200,000</u>	<u>Common</u>	<u>.0075</u>	<u>Yes</u>	Christian Leomporra	<u>Conversion of Series B Shares</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>7/9/21</u>	<u>Cancelation</u>	<u>9,000</u>	<u>Series B Preferred</u>	<u>N/A</u>	<u>N/A</u>	Christian Leomporra			
<u>7/13/21</u>	<u>New Issuance</u>	<u>250.000</u>	<u>Common</u>	<u>.10</u>	<u>No</u>	Josh York	<u>Subscription Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>08/10/21</u>	<u>New Issuance</u>	<u>1,700.000</u>	<u>Common</u>	<u>.085</u>	<u>No</u>	Fortified Management, LLC (Thomas Scipione)	<u>Settlement Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>08/10/21</u>	<u>New Issuance</u>	<u>300.000</u>	<u>Common</u>	<u>.085</u>	<u>No</u>	Jody Samuels	<u>Settlement Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>08/18/2021</u>	<u>New Issuance</u>	<u>1,500.000</u>	<u>Common</u>	<u>.10</u>	<u>No</u>	Dan Broudy	<u>Subscription Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>08/18/2021</u>	<u>New Issuance</u>	<u>1,500.000</u>	<u>Common</u>	<u>.10</u>	<u>No</u>	Arnold Broudy	<u>Subscription Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>08/19/2021</u>	<u>New Issuance</u>	<u>1,111,111</u>	<u>Common</u>	<u>.09</u>	<u>No</u>	Da Costa	<u>Subscription Agreement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>09/01/2021</u>	<u>New Issuance</u>	<u>300.000</u>	<u>Common</u>	<u>.10</u>	<u>No</u>	Michael K Fish	<u>Board Fee</u>	<u>Restricted</u>	<u>4(a)(2)</u>

<u>09/17/2021</u>	New Issuance	<u>250,000</u>	<u>Common</u>	<u>.10</u>	<u>No</u>	Nicholas Boulis	<u>Scientific Advisory Board Fee</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>09/27/2021</u>	New Issuance	<u>250,000</u>	<u>Common</u>	<u>.11</u>	<u>No</u>	Catherine Sohn	<u>Advisor Fee</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>10/12/2021</u> -	New Issuance	12,500,000	<u>Common</u>	<u>.114</u>	<u>NA</u>	Mid Atlantic BioTherapeutics/ (David Horn, M.D.)	License Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/12/2021</u>	New Issuance	403,225	<u>Common</u>	<u>.062</u>	<u>NA</u>	Keller Family Trust/ (Adam Keller)	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/10/2021</u>	New Issuance	2,439,025	<u>Common</u>	<u>.041</u>	<u>NA</u>	Rochelle Langer	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/10/2021</u>	New Issuance	609,757	<u>Common</u>	<u>.041</u>	<u>NA</u>	Zabrina Langer	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/13/2021</u>	New Issuance	609,757	<u>Common</u>	<u>.041</u>	<u>NA</u>	Charles McHenry	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/13/2021</u>	New Issuance	1,000,000	<u>Common</u>	<u>.041</u>	<u>NA</u>	Arnold Broudy	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/13/2021</u>	New Issuance	1,000,000	<u>Common</u>	<u>.041</u>	<u>NA</u>	Dan Broudy	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/13/2021</u>	New Issuance	1,219,513	<u>Common</u>	<u>.041</u>	<u>NA</u>	GG Capital (Joseph Gantz)	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/13/2021</u>	New Issuance	609,757	<u>Common</u>	<u>.041</u>	<u>NA</u>	Rita Michaelson	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/14/2021</u>	New Issuance	200,000	<u>Common</u>	<u>.106</u>	<u>Na</u>	Max McKenna	Website Maintenance	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/15/2021</u>	New Issuance	1,000,000	<u>Common</u>	<u>.041</u>	<u>NA</u>	Justin DaCosta	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/15/2021</u>	New Issuance	609,757	<u>Common</u>	<u>.041</u>	<u>NA</u>	IPG Investments, LLC / (Bruce Combe)	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/15/2021</u>	New Issuance	609,757	<u>Common</u>	<u>.041</u>	<u>NA</u>	Hancock Western Investments, LLC / (David Hancock)	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/15/2021</u>	New Issuance	609,757	<u>Common</u>	<u>.041</u>	<u>NA</u>	Steven Nelson	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/15/2021</u>	New Issuance	1,219,513	<u>Common</u>	<u>.041</u>	<u>NA</u>	Stanley Silver	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/15/2021</u>	New Issuance	1,219,513	<u>Common</u>	<u>.041</u>	<u>NA</u>	Harry Silver	Subscription Agreement	<u>Restricted</u>	<u>4(a)(2)</u>
<u>01/10/2022</u>	New Issuance	1,000,000	<u>Common</u>	<u>.05175</u>	<u>No</u>	Paul Michaels	Officer Bonus	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/12/2022</u>	New Issuance	2,439,026	<u>Common</u>	<u>.02</u>	<u>No</u>	GG Capital, LLC (Joseph Gantz)	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>

<u>3/3/2022</u>	<u>1,142,857</u>	<u>1,142,857</u>	<u>-0-</u>	<u>05/16/2023</u>	Upon event of default, 70% of lowest closing price for prior 20 trading days.	Puritan Partners, LLC (Richard Smithline)	Loan
<u>5/27/2022</u>	<u>200,000</u>	<u>200,000</u>	<u>-0-</u>	<u>05/27/2023</u>	None	UC ASSET LP (Greg Bankston)	Loan
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
 IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: **Michael K. Fish**
Title: **Certified Public Accountant**
Relationship to Issuer: **Director**

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;
D. Statement of Income;
E. Statement of Cash Flows;
F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
G. Financial notes; and
H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

The unaudited financial statements for the period ended 12/30/2022 are attached hereto

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three (3) different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform, based on a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease with the goal of being in the clinic in 2023 for a first in human trial of its metformin-based eye drop. The trial will be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI.

- B. Please list any subsidiaries, parents, or affiliated companies.

N/A

- C. Describe the issuers' principal products or services.

The Company is focused on developing therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. The Company operates on an outsource model, where it's core management group oversees a network of subject matter experts, clinical advisors, manufacturing vendors and regulatory consultants.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used, or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties, or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company utilizes virtual office space at a cost of \$99 per month.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Paul M. Michaels	Officer and Director	Boca Raton, FL	<u>29,609,695</u> 6,000,000	Common Series C Preferred	5.18% 20%	
Barry A. Ginsberg, O.D.	Officer and Director	Boca Raton, FL	<u>71,676,362</u> 6,000,000	Common Series C Preferred	12.38% 20%	
Michael K. Fish	Director	Miami, FL	500,000	Common	<1%	
I Richard Garr, J.D.	Officer	Delray Beach, FL	<u>14,550,000</u> 6,000,000	Common Series C Preferred	<u>2.55%</u> 20%	
Ronald W. Bordens, Ph.D.	Officer	Boynton Beach, FL	250,000 6,000,000	Common Series C Preferred	<u><1%</u> 20%	
Michael J. Grace, Ph.D.	Advisor	Hamilton, NJ	250,000 6,000,000	Common Series C Preferred	<u><1%</u> 20%	
Cary Sucoff, J.D.	Director	Cold Spring Harbor, NY	-0-	N/A	N/A	
Lawrence Zaslow	Director	Chappaqua, NY	-0-	N/A	N/A	

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Jonathan Leinwand
Firm: Jonathan D. Leinwand, P.A.
Address 1: 18305 Biscayne Blvd., Suite 200
Address 2: Aventura, FL 33180
Phone: 954-903-7856
Email: jonathan@jdlpa.com

Accountant or Auditor

Name: Michael K. Fish
Firm: Michael K. Fish, CPA PA
Address 1: 7700 N Kendall Dr. #405
Address 2: Miami, FL 33156
Phone: 305-279-8484

Investor Relations

N/A

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Securities Counsel

Name: Raul Silvestre
Firm: Silvestre Law Group, P.C.
Address 1: 2629 Townsgate Road, Suite 215
Address 2: Westlake Village, CA 91361
Phone: 818-597-7552
Email: rsilvestre@silvestrelaw.com

Securities Counsel

Name: Amit Hazan
Firm: Lucosky Brookman, LLP
Address 1: 101 S. Wood Avenue
Address 2: Woodbridge, N.J. 08830
Phone: 732-395-4400
Email: ahazan@lucbro.com

Accountant or Auditor

Name: Tod Edgecomb
Firm: Marcum, LLP
Address 1: 730 3rd Avenue, 11th Floor,
Address 2: New York, NY 10017
Phone: 212-485-5500
Email: tod.edgecomb@marcumllp.com

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, I Richard Garr, certify that:

1. I have reviewed this annual disclosure statement of Curative Biotechnology Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 31, 2023 [Date]

/s/ I Richard Garr [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, I Richard Garr, certify that:

1. I have reviewed this annual disclosure statement of Curative Biotechnology Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 31, 2023 [Date]

/s/ I Richard Garr [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

INDEX TO UNAUDITED FINANCIAL STATEMENTS

Balance Sheets F-2

Statements of Operations F-3

Statement of Deficiency in Stockholders' Equity F-4

Statements of Cash Flows F-5

Notes to Financial Statements F-6

Curative Biotechnology, Inc
Balance Sheets
December 31,
(Unaudited)

	2022	2021
ASSETS		
CURRENT ASSETS		
Cash	\$ 58,668	\$ 670,263
Subscription receivable	-	25,000
Prepaid expenses	10,000	58,642
Total current assets	68,668	753,905
FIXED ASSETS		
Property and equipment	6,834	6,834
Accumulated depreciation	(570)	(114)
Total fixed assets	6,264	6,720
OTHER ASSETS		
Deferred offering costs	390,104	92,975
Intangible assets, net	1,624,155	1,558,550
Total other assets	2,014,259	1,651,525
Total Assets	\$ 2,089,191	\$ 2,412,150
LIABILITIES AND DEFICIENCY IN STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES		
Accounts payable and accrued liabilities	\$ 3,394,544	\$ 726,904
Liability to issue common shares	21,911	3,431
Short term note payable	200,000	-
Short term convertible note payable, net of discounts	870,648	-
Total current liabilities	4,487,103	730,335
Total Liabilities	4,487,103	730,335
Commitments and Contingencies		
Preferred stock, Series A, 0 and 134,109,750 shares issued and outstanding	-	-
Preferred stock, Series C, 30,000,000 and 30,000,000 shares issued and outstanding	18,131,825	18,043,557
DEFICIENCY IN STOCKHOLDERS' EQUITY		
Preferred stock, \$0.0001 par value, authorized 200,000,000 shares, Series B 197,000 and 81,000 shares issued and outstanding	20	8
Common stock, \$0.0001 par value, authorized 1,100,000,000 shares; 579,271,135 and 570,651,636 shares issued and outstanding	57,927	57,065
Additional paid-in capital	12,022,514	10,498,221
Accumulated deficit	(32,610,198)	(26,917,036)
Total deficiency in stockholders' equity	(20,529,737)	(16,361,742)
Total Liabilities and Deficiency in Stockholders' Equity	\$ 2,089,191	\$ 2,412,150

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
Statements of Operations
Year ended December 31,
(Unaudited)

	<u>2022</u>	<u>2021</u>
REVENUES	\$ -	\$ -
COST OF REVENUES	<u>-</u>	<u>-</u>
GROSS MARGIN	-	-
OPERATING EXPENSES:		
General and administrative expenses	1,945,653	4,211,355
Research and development expenses	2,482,079	779,275
Impairment of long-lived assets	3,800	16,958
Depreciation and amortization	<u>7,956</u>	<u>6,744</u>
Total expenses	<u>4,439,488</u>	<u>5,014,332</u>
Loss from operations	(4,439,488)	(5,014,332)
Other (income) expense:		
Other (income)	(4,914)	-
Interest expense	1,170,319	176,672
Loss on debt extinguishment	<u>-</u>	<u>149,350</u>
Total other (income) expense	<u>1,165,405</u>	<u>326,022</u>
Net loss	(5,604,893)	(5,340,354)
Series C deemed dividend	<u>(88,269)</u>	<u>(13,477,055)</u>
Net loss to common shareholders	<u>\$ (5,693,162)</u>	<u>\$ (18,817,409)</u>
(Loss) income per basic weighted average common share	<u>\$(0.01)</u>	<u>\$(0.04)</u>
Number of weighted average basic and diluted common shares outstanding	<u>572,009,911</u>	<u>500,981,957</u>

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
Statement of Deficiency in Stockholders' Equity
(Unaudited)

	Number of Shares		Par Value		Additional Paid-in Capital	Accumulated Deficit	Total Deficiency in Stockholders' Equity
	Common	Preferred	Common	Preferred			
BALANCE , January 1, 2021	333,000,327	164,402,750	\$ 33,300	\$29	\$ 3,544,658	\$ (8,099,627)	\$ (4,521,641)
Common shares issued for services	8,715,000	-	872	-	539,264	-	540,136
Common shares issued for intangible assets	12,500,000	-	1,250	-	1,423,750	-	1,425,000
Warrants issued in connection with debt	-	-	-	-	9,533	-	9,533
Warrants and options issued for services	-	-	-	-	485,487	-	485,487
Common stock issued for conversion of Preferred stock Series A	135,836,702	(134,109,750)	13,584	*	1,550,667	-	1,564,251
Common stock issued for conversion of Preferred stock Series B	28,266,666	(212,000)	2,826	(21)	(2,805)	-	0
Shares issued for cash	27,520,442	-	2,752	-	1,570,248	-	1,573,000
Shares issued to convert debt	10,937,499	-	1,094	-	655,156	-	656,250
Warrant exercises for cash	10,500,000	-	1,050	-	523,950	-	525,000
Shares issued to settle payables	375,000	-	37	-	11,213	-	11,250
Shares issued to settle debt	2,000,000	-	200	-	179,800	-	180,000
Shares issued to settle liability to issue shares	1,000,000	-	100	-	7,300	-	7,400
Series C deemed dividend	-	-	-	-	*	(13,477,055)	(13,477,055)
Net loss	-	-	-	-	-	(5,340,354)	(5,340,354)
BALANCE , December 31, 2021	570,651,636	30,081,000	\$ 57,065	\$ 8	\$ 10,498,221	\$ (26,917,036)	\$ (16,361,743)
Warrant exercises for cash	7,619,499	-	762	-	151,628	-	152,390
Shares issued for cash	-	116,000	-	12	115,988	-	116,000
Shares issued for services	1,000,000	-	100	-	51,650	-	51,750
Options issued for services	-	-	-	-	155,250	-	155,250
Warrants issued for services	-	-	-	-	12,976	-	12,976
Warrants issued in connection with debt	-	-	-	-	1,036,801	-	1,036,801
Series C deemed dividend	-	-	-	-	*	(88,269)	(88,269)
Net loss	-	-	-	-	-	(5,604,893)	(5,604,893)
BALANCE , December 31, 2022	<u>579,271,135</u>	<u>30,197,000</u>	<u>\$ 57,927</u>	<u>\$ 20</u>	<u>\$ 12,022,514</u>	<u>\$ (32,610,198)</u>	<u>\$ (20,529,738)</u>

* Series A and Series C Preferred Stock amounts reflected in mezzanine equity

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
Statements of Cash Flows
Year ended December 31,
(Unaudited)

	2022	2021
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	(\$5,604,893)	(\$5,340,354)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	7,956	6,744
Share based compensation	278,804	2,889,567
Amortization of warrant discount	810,073	2,545
Amortization of Original Issue Discount	119,048	122,129
Amortization of debt fees discount	108,357	-
Loss on debt extinguishment	-	149,350
Impairment of long lived assets	3,800	16,958
Changes in operating assets and liabilities		
Decrease (increase) in stock subscription receivable	25,000	(25,000)
Decrease (increase) in prepaid expenses	48,642	(18,294)
Increase in accounts payable and accrued expenses	2,667,640	592,320
Net cash used in operating activities	(1,535,573)	(1,604,035)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of fixed assets	-	(6,834)
Purchase of intangible assets	(76,905)	(14,500)
Net cash used in investing activities	(76,905)	(21,334)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Cash received for issuance of common stock	-	1,573,000
Cash received for issuance of Series B preferred stock	116,000	-
Cash received for exercise of warrants	152,390	525,000
Repayments on note payable	(86,700)	-
Cash paid for deferred offering costs	(250,779)	(92,975)
Payments on related party notes payable	-	(50,000)
Cash received from convertible note payable	869,972	-
Cash received from third party note payable	200,000	110,000
Net cash provided by financing activities	1,000,883	2,065,025
Net increase in cash	(611,595)	439,656
CASH, beginning of year	670,263	160,607
CASH, end of year	\$ 58,668	\$ 600,263
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:		
Interest paid in cash	\$ 124,886	\$ 10,000
Income taxes paid in cash	\$ -	\$ -
Non-Cash Financing Activities:		
Common shares issued for intangible assets	\$ -	\$ 1,425,000
Common shares issued upon conversion of debt	\$ -	\$ 656,250
Common shares issued upon conversion of preferred stock	\$ -	\$ 1,564,251
Warrants issued as debt discount	\$ 1,036,801	\$ 9,533
Series C preferred stock deemed dividend	\$ 88,269	\$ 13,477,055
Common shares issued to settle liabilities	\$ -	\$ 198,650

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 1 - NATURE OF OPERATIONS

Curative Biotechnology Inc. (f/k/a Connectyx Technologies Holdings Group, Inc.), (CUBT), is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change November 30, 2020, which conducts business from its headquarters in Boca Raton, Florida. Curative Biotechnology, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined "Orphan Diseases" with patient populations under 200,000 in the United States. The company leverages management's experience and business relationships with Life Science research institutions as well as Life Science industry members to acquire Life Science candidates that fit within the company's business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

a) Basis of Presentation The accompanying financial statements have been prepared in accordance with Generally Accepted Accounting Principles ("GAAP") in the United States of America ("U.S.") as promulgated by the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC").

b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

(c) Cash and equivalents The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents at December 31, 2022 and 2021.

(d) Prepaid expenses From time to time, the Company may prepay expenses either through the transfer of cash, assets or the issuance of securities. Prepaid expenses are amortized over the period of benefit.

(e) Property and equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.

(f) Intangible Assets The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any.

Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives.

Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified.

(g) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

(h) Financial Instruments and Fair Value Measurements

ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments.

FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

(i) Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

(j) Revenue Recognition The Company adopted Accounting Standards Codification, (“ASC”), 606, “Revenue from Contracts with Customer” on January 1, 2018. This revenue recognition standard has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; e) Recognize revenue when (or as) performance obligations are satisfied. The Company’s financial statements are prepared under the accrual method of accounting. Revenues will be recognized when pervasive evidence of an arrangement exists, services have been rendered (product delivered), the sales price is fixed or determinable, and collectability is reasonably assured. This occurs only when the product(s) is ordered and subsequently delivered.

(k) Stock based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award. The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50, for share-based payments to non-employees, compensation expense is determined at the “measurement date.” The expense is recognized over the service period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date.

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

(l) Income Taxes Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the consolidated financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes. Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities.

(m) Net income (loss) per share Basic loss per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. There were no dilutive common stock equivalents for the years ended December 31, 2022 and 2021.

(n) Recent Accounting Pronouncements The Company has considered recent accounting pronouncements during the preparation of these financial statements.

NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company's financial position and operating results raise substantial doubt about the Company's ability to continue as a going concern, as reflected by the net loss of approximately \$5.6 million and accumulated deficit of approximately \$32.6 million through December 31, 2022. The ability of the Company to continue as a going concern is dependent upon commencing operations, developing sales and obtaining additional capital and financing. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is currently seeking additional capital to allow it to grow its operations

NOTE 4 - INTANGIBLE ASSETS

During the 4th quarter 2021, the Company acquired the following intangible asset:

(a) MABT Covid-19 license The Company entered into a licensing agreement with Mid-Atlantic BioTherapeutics, Inc., (MABT), to license MABT's COVID-19 vaccine which is composed of a recombinant S1 and S2 protein from SARS-CoV-2 plus an IMT504 adjuvant. The Company issued 12,500,000 shares of common stock valued at \$1,425,000 to acquire this license.

During the 4th quarter 2020, the Company acquired the following intangible assets:

(b) Website In December 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of \$22,500, one-half in cash and one-half in common stock of the Company. The Company expects to amortize this cost over 3 years once it is operational.. This website was placed into service in March 2021. Amortization expense for the year ended December 31, 2021 was \$6,250.

In March 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of \$15,000, for which the Company issued 1,500,000 shares of common stock.

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 4 - INTANGIBLE ASSETS, continued

(c) IMT504 Patent license In October 2020, the Company entered into a license agreement with MidAtlantic BioTherapeutics, Inc., (MABT), to license the development of a pharmaceutical compound known as IMT504, as immunotherapy for late stage symptomatic rabies. The license is for worldwide use. There are certain conditions to the license, principally that the Company raise \$6.5 million to fund the development. There is not a time limit on raising these funds unless the Company utilizes a public offering process, such as Regulation A.

The total cost for this license is 20 million shares of the Company's common stock, issuable in three tranches - 1- 7 million shares upon execution of the license (which have been issued, valued at \$91,000), 2- 6.5 million shares upon the submission of an Investigational New Drug (IND) to the FDA and 3- 6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing IMT504.

(d) National Institute of Health (NIH) Patent license #1 In October 2020, the Company entered into an exclusive 24 month evaluation license of Provisional Patent Application No. 62/199,707, filed July 31, 2015; PCT Application No. PCT/US2016/044777 filed July 29, 2016 and Patent No. 10,548,987 issued February 4, 2020. This license is for the evaluation of and development of an anti-CD56 antibody drug conjugate for the treatment of glioblastoma. Should the Company develop a marketable product, the Company is then required to negotiate a new license with appropriate royalties.

This license calls for the payment of a non-creditable non-refundable license issue royalty of \$10,000, paid ½ at issuance and ½ on the one year anniversary.

In October 2022, the NIH agree to extend this agreement for an additional 12 months.

(e) National Institute of Health (NIH) Patent license #2 In January 2021 the Company entered into an NIH exclusive 36 month worldwide license of Provisional Patent Application No. 62/899,899, filed September 13, 2019 and PCT Application No. PCT/US2020/050540 filed September 11, 2020. This license is for the development of ocular metformin formulation for the treatment of retinal degenerative diseases.

This license requires two separate royalty streams of payments:

First is a royalty equal to the unreimbursed patent expenses paid by NIH, with an initial amount of \$8,500 due within 30 days of execution of the license. At the first anniversary of the license NIH will supply a statement of additional unreimbursed patent expenses paid by NIH during the year, of which the Company is required to pay 50%, with the remaining balance due on the third anniversary.

Second is an ongoing royalty schedule: an initial royalty of \$5,000 upon execution of the license, and annually thereafter as the minimum royalty amount. The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of \$45,000. There are three benchmark royalties - \$75,000 upon the initiation of the first Phase 2 Clinical Study; \$300,000 upon the completion of Phase 3 Clinical Study and \$600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of \$100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty.

The patent rights and patent licenses are under development, therefore amortization of the costs has not commenced, as these patent rights and licenses have not been placed in service.

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 5 - RELATED PARTY TRANSACTIONS

From time to time the Company may enter into non-arms length transactions with related parties, however the Company exercises its best efforts to ensure that such transactions are valued on a basis comparable to a true arms length transaction.

During the second quarter of 2021, the remaining two notes from officers of the Company, totaling \$40,000 of principal and \$10,000 of OID, were repaid in cash.

NOTE 6 - NOTES PAYABLE

During the second quarter of 2022, The Company issued a promissory note in exchange for \$200,000 in cash. This note carries a 12% interest rate, interest payable monthly, and a six month maturity. At maturity, the maturity was extended for an additional six months and the interest rate was increased to 18%, interest payable monthly.

During the second quarter of 2021, the remaining two notes, totaling \$40,000 of principal and \$10,000 of OID, were repaid in cash.

During the first quarter 2021, 13 of the 15 total notes for a total of \$656,250, including OID, were converted into 10,937,499 shares of common stock at the rate of \$0.06 per share..

During the first quarter of 2021, the Company entered into two (2) notes payable with a face amount of \$137,500, including 25% Original Issue Discount (OID), for a total amount of cash received of \$110,000. The notes are identical and carry a maturity of six months from inception and a 25% OID. The maturity is extendable at the Company's option for up to three months with a 3% per month extension fee. In connection with the notes, the Company issued warrants to purchase 1,100,000 shares of common stock of the Company, which were recorded as a discount in the amount of \$9,533, which is being amortized over the term of the notes. These notes are collateralized by Preferred C shares representing 9.24% of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral.

NOTE 7 - CONVERTIBLE SENIOR SECURED NOTE PAYABLE

In March 2022, the Company issued a 12-month Senior Secured Note with a face amount of \$1,142,857, with a stated 12.5% original issue discount (OID). The Note carries a 12.5% interest rate with interest-only payable monthly from April through August 2022. The Company received \$869,972 in cash, net of the OID of \$142,857 and legal and other fees in the amount of \$125,714.

Beginning in September 2022, the Company is required to make monthly redemptions at the rate of 110% of one seventh of the original principal amount, (\$179,592), plus interest. It also carries a mandatory prepayment at 125% of the original principal amount, or \$1,428,571, less any redemptions made, upon the completion of a Qualified Offering, as defined.

The Note is convertible into common stock of the Company upon an event of default, as defined. The lender received five-year warrants to purchase 22,857,143 shares of common stock of the Company, with an exercise price of \$0.0001 per share. These warrants were recorded as debt discount in the amount of \$0.9 million which is being amortized over the term of the Note. The warrants can be exercised on a cash-less basis if a registration statement for the common shares underlying the warrants is not declared effective by September 2022.

The Note is secured by all the tangible and intangible assets of the Company.

In August 2022, the Company and the lender agreed to the first modification of the Note. In exchange for a one-month extension to begin the principal payments under this Note, the parties agreed to reduce the qualified offering amount from \$10 million to \$7.2 million; modify the payment schedule from seven (7) months to six (6) months. In addition, the lender received 1,904,762 additional warrants having a fair value of \$58,884, which were recorded as an additional debt discount and amortized over the remaining life of the Note.

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 7 - CONVERTIBLE SENIOR SECURED NOTE PAYABLE, continued

In October 2022, the Company and the lender agreed to the second modification of the Note. The first payment due was delayed from October 2 to October 17.

In October 2022, the Company and the lender agreed to the third modification of the Note. The first payment due was delayed from October 17 to November 2. The lender received 1,904,762 additional warrants having a fair value of \$36,053, which were recorded as an additional debt discount and amortized over the remaining life of the Note.

In November 2022, the Company and the lender agreed to the fourth modification of the Note. The first payment due was delayed from November 2 to November 17.

In November 2022, the Company and the lender agreed to the fifth modification of the Note. The first payment due was delayed from November 17 to December 17. The lender received 1,904,762 additional warrants having a fair value of \$37,955, which were recorded as an additional debt discount and amortized over the remaining life of the Note.

In December 2022, the Company and the lender agreed to the sixth modification of the Note. The first payment due was delayed from December 17 to January 17. The lender received 1,904,762 additional warrants having a fair value of \$33,936, which were recorded as an additional debt discount and amortized over the remaining life of the Note.

Subsequent to December 31, 2022, certain terms of the note were amended four more times.

NOTE 8 - LIABILITY TO ISSUE COMMON STOCK

At December 31, 2022, the Company has a liability to issue 662,500 shares of the Company's common stock in exchange for services valued at \$24,511.

NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY

At December 31, 2022 and 2021, the Company has 1,100,000,000 shares of par value \$0.0001 common stock authorized and 579,271,135 and 570,651,636 issued and outstanding, respectively. At December 31, 2022 and 2021, the Company has 200,000,000 shares of \$0.0001 par value preferred stock authorized.

The Company accounts for the Series A and Series C preferred stock in accordance with FASB Accounting Standards Codification (ASC) 480, as mezzanine equity due to Series A having a redemption provision and Series C being convertible into a variable number of common shares.

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued

	Series A		Series B		Series C		Total	
	No. Shares	Par	No. Shares	Par	No. Shares	Par	No. Shares	Par
January 1, 2021	134,109,750	\$ 13,411	293,000	\$ 29	30,000,000	\$ 3,000	269,402,750	\$ 16,440
Conversion to common shares	(134,109,750)	(13,411)	(212,000)	(21)	-	-	(134,321,750)	(13,432)
December 31, 2021	-	-	81,000	8	30,000,000	-	135,081,000	3,008
Issuance of shares for cash			116,000	12	-	-	116,000	12
December 31, 2022	-	\$ -	197,000	\$ 20	30,000,000	\$ 0	135,197,000	\$ 3,020

The preferred shares have the following respective rights and privileges:

Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date; is convertible into common stock aggregating 35% of the total issued and outstanding common shares at conversion date post conversion; are redeemable at the Company's option for the greater of 45% of the total market value of the common shares or the calculation of the book value of the Company made by an independent audit firm or \$5,000,000.

Series B Preferred are convertible in common shares of common stock at a conversion price of \$0.0075 per share; are redeemable at the Company's option at a price of 125% of the purchase price paid for the shares; carry one vote for each common share that the Series B is convertible into at the record date; are senior to all other securities in the event of a liquidation.

Series C Preferred are convertible into common stock aggregating 30% of the total issued and outstanding common shares at conversion date post conversion; carry ten votes for each common share that the Series C is convertible into at the record date.

During the fourth quarter 2022, the Company issued 7,619,499 shares of common stock and 7,619,499 warrants for the purchase of common stock with an exercise price of \$0.02 per share in exchange for \$152,390 in cash. These shares resulted from the exercise of 7,619,499 warrants that previously had exercise prices of \$0.09, \$0.11 and \$0.15 per share. The Company agreed to modify the exercise price to \$0.02 per share. The Company also issued 116,000 shares of Series B preferred stock in exchange for \$116,000 in cash.

During the first quarter 2022, the Company issued 1,000,000 shares of common stock to one employee for part services valued at \$51,750.

During the fourth quarter 2021, the Company issued 13,159,331 shares of common stock and 25,915,437 warrants for the purchase of common stock in exchange for \$523,000 in cash and \$25,000 in deposit in transit. During the fourth quarter 2021, the Company issued 200,000 shares of common stock, valued at \$21,960 for services. During the fourth quarter 2021, the Company issued 12,500,000 shares of common stock, valued at \$1,425,000 for the license to MABT's COVID-19 vaccine.

During the third quarter 2021, the Company issued 4,361,111 shares of common stock and 4,236,111 warrants for the purchase of common stock in exchange for \$425,000 in cash. During the third quarter 2021, the Company issued 250,000 shares of common stock, valued at \$22,500, to an individual for services to be rendered as a member of the Company's Advisory Board. These shares vest 60,000 immediately, 60,000 in December 2021, 60,000 in April 2022 and 70,000 in August 2022. During the third quarter 2021, the Company issued 300,000 shares of common stock, valued at \$36,720, to an individual for services rendered as a member of the Company's Board of Directors. During the third quarter 2021, the Company issued 250,000 shares of common stock, valued at

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued

\$28,475, to an individual for services to be rendered as a member of the Company's Advisory Board. These shares vested immediately. During the third quarter the Company issued 2,000,000 shares of common stock, valued at \$180,000, to settle the lawsuit brought to enforce the convertible note. During the third quarter 2021, 9,000 shares of the Series B preferred stock was converted into 1,200,000 shares of common stock.

During the second quarter 2021, the Company issued 10,000,000 shares of common stock and 5,000,000 warrants for the purchase of common stock in exchange for \$600,000 in cash. The warrants mature in May 2026, and carry an exercise price of \$0.11 per share. During the second quarter 2021, the Company issued 1,000,000 shares of common stock to settle the liability to issue shares.

During the second quarter 2021, the Company issued 250,000 shares of common stock to an individual for services to be rendered as a member of the Company's Advisory Board. These shares vest 60,000 immediately, 60,000 in August 2021, 60,000 in December 2021 and 70,000 in April 2022. During the second quarter 2021, the Company issued 840,000 shares of common stock to an employee for services to be rendered. These shares vest 210,000 immediately, 210,000 in September 2021, 210,000 in December 2021 and 210,000 in March 2022. 840,000 of these shares to the two (2) individuals were issued and recorded as a prepaid expense to be amortized as they vest.

During the first quarter 2021, the Company issued 125,000 shares of common stock in exchange for services valued at \$5,575, or \$0.0446 per share. During the first quarter 2021, the Company issued 375,000 shares of common stock to settle a payable in the amount of \$11,250. During the first quarter 2021, all of the Series A preferred stock was converted into 135,836,702 shares of common stock. During the first quarter 2021, 203,000 shares of the Series B preferred stock was converted into 27,066,666 shares of common stock. During the first quarter of 2021, 13 of the 15 note holders converted their note receivable into shares of common stock at the rate of \$0.06 per share, for a total of 10,937,499 shares of common stock for a total of \$656,250 convertible debt. During the first quarter 2021, the Company issued 10,500,000 shares of common stock upon receipt of \$525,000 in cash for the exercise of 10,500,000 warrants. During the first quarter 2021, the Company issued 6,500,000 shares of common stock for the exercise of 6,500,000 warrants in exchange for services valued at \$325,000.

During the 1st quarter 2020, the Company issued 1,500,000 shares of common stock in exchange for services valued at \$15,000, or \$0.01 per share.

A deemed dividend for the Series C preferred stock is calculated and recorded as shares of common stock are issued. This is calculated as the increase in common shares that the Series C would receive upon conversion, as a result of the change in the number of common shares issued and outstanding during the period multiplied by the closing price of the common stock at the end of the period. The deemed dividend was \$88,269 and \$13,477,055 for the year ended December 31, 2022 and 2021 respectively.

NOTE 10 - WARRANTS

During the fourth quarter 2022, the Company issued 7,619,499 warrants for the purchase of common stock with an exercise price of \$0.02 per share in conjunction with the exercise of 7,619,499 warrants for \$152,390.

During the fourth quarter 2022, The Company and the lender agreed to five modifications of the Note. In exchange for ultimately a three and a half-month extension of the first payment date, the lender received 1,904,762 additional warrants three times having a fair value of \$36,054, \$37,955 and \$33,936, which was recorded as an additional debt discount and amortized over the remaining life of the Note.

During the third quarter 2022, The Company and the lender agreed to a modification of the Note. In exchange for a one-month extension to begin the principal payments under this Note, the parties agreed to reduce the qualified offering amount from \$10 million to \$7.2 million; modify the payment schedule from seven (7) months to six (6) months. In addition, the lender received 1,904,762 additional warrants having a fair value of \$58,884, which will be recorded as an additional debt discount and amortized over the remaining life of the Note.

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 10 - WARRANTS, continued

The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life - three or five years; stock price between \$0.0179 and \$0.031; volatility between 38.46 and 113.10; exercise price of \$0.0001 and bond equivalent yield rate between 3.02% and 4.25%.

During the fourth quarter 2021, the Company issued 403,225 warrants for the purchase of common stock of the Company in conjunction with the sale of 403,225 shares of common stock for cash. These warrants expire in December 2024 and have an exercise price of \$0.11 per share. During the fourth quarter 2021, the Company issued 25,512,212 warrants for the purchase of common stock of the Company in conjunction with the sale of 12,756,106 shares of common stock for cash and subscription receivable. These warrants expire in December 2024 and have an exercise price of \$0.09 and \$0.15 per share.

During the third quarter 2021, the Company issued 4,236,111 warrants for the purchase of common stock of the Company in conjunction with the sale of 4,361,111 shares of common stock for cash. These warrants expire in July and August 2026 and have an exercise price of \$0.15 and \$0.14 per share. During the third quarter 2021, the Company issued 1,000,000 warrants for the purchase of common stock of the Company in exchange for services as a member of the Board of Directors. These warrants expire in July 2024 and have an exercise price of \$0.124 per share and have a cash-less exercise provision. These warrants were recorded at a total value of \$34,382.

During the second quarter 2021, the Company issued 5,000,000 warrants for the purchase of common stock of the Company in conjunction with the sale of 10,000,000 shares of common stock for cash. These warrants expire in May 2026 and have an exercise price of \$0.11 per share. During the second quarter 2021, the Company issued 5,000,000 warrants for the purchase of common stock of the Company in exchange for services as a member of the Board of Directors. These warrants expire in June 2024 and have an exercise price of \$0.20 per share. The warrants were recorded at a total value of \$87,249. During the second quarter 2021, the Company issued 3,000,000 warrants for the purchase of common stock of the Company in exchange for legal services. These warrants expire in May 2026 and have an exercise price of \$0.10 per share. The warrants were recorded at a total value of \$155,717.

During the second quarter 2021, the Company issued 1,000,000 warrants for the purchase of common stock of the Company in exchange for services. These warrants expire in May 2026 and have an exercise price of \$0.10 per share. The warrants were recorded at a total value of \$51,906 and vest 250,000 shares on May 20, 2021 and September 20, 2021, January 20, 2022 and May 20, 2022. During the first quarter 2021, the Company issued 10,500,000 shares of common stock upon receipt of \$525,000 in cash for the exercise of 10,500,000 warrants. During the first quarter 2021, the Company issued 6,500,000 shares of common stock in exchange for services valued at \$325,000 for the exercise of 6,500,000 warrants.

In the first quarter 2021, the Company issued 1,100,000 warrants for the purchase of common stock of the Company in conjunction with the short term debt at the rate of 10 warrants for each \$1 loaned. These warrants carry an expiration of thirty six months from issuance; an exercise price of \$0.05 per share and are exercisable immediately. The warrants were recorded at a total value of \$9,533.

In the first quarter 2021, the Company issued 5,000,000 warrants for services. These warrants carry an expiration of 60 months from issuance and an exercise price of \$0.05 per share. The warrants were recorded at a total value of \$40,600.

The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life - three or five years; stock price between \$0.04 and \$0.10; volatility between 60.51 and 31.56; exercise price between \$0.05 and \$0.2 and bond equivalent yield rate between 0.09% and 0.83%.

NOTE 11 - OPTIONS

In the third quarter of 2021, the Company issued options in conjunction with an agreement for Board of Advisor services and the evaluation of certain potential intangible asset acquisitions. These options call for an undivided 1% of the fully diluted issued and outstanding shares upon exercise. These options amounted to 8,081,037 shares at issuance date. These options contain a single recalculation upon the completion of a reverse split of the existing common stock and the Company raising a minimum of \$5 million in an offering. These options carry an exercise price of \$0.11 per share and expire in September 2031. These options were valued at \$436,908 and vest 50% upon issuance and 50% in September 2022.

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 11 - OPTIONS, continued

The method utilized to value the options was the Black-Scholes model with the following assumption ranges: Expected life - ten years; stock price \$0.114; volatility 35.13; exercise price \$0.11 and bond equivalent yield rate 1.47%.

NOTE 12 - EQUITY INCENTIVE PLAN

On August 26, 2021, the Company adopted a equity incentive plan providing for the issuance of shares of common stock, options or SARs with a rolling maximum number equal to 10% of the issued and outstanding Common Shares set at the beginning of each fiscal year. The Company may grant incentives to its directors, officers, employees and service providers. The options are exercisable for a maximum of up to ten years from the date of grant and may be subject to vesting provisions as set by the Plan Administrator.

During the quarter ended March 31, 2022, a total of 1,000,000 shares of common stock and 7,456,500 options at a weighted average exercise price of \$0.0518 per share were granted to employees exercisable for a period of five years with immediate vesting. The weighted-average fair value attributable to options granted in 2022 was \$0.0208.

The fair value of the stock options recognized in the period has been estimated using the Black-Scholes option pricing model. Assumptions used in the pricing model are as provided below.

Risk-free interest rate	1.55%
Exercise price	\$ 0.00518
Expected life	5 years
Expected volatility	44.12%
Expected dividends	-

The Company recognized equity incentive expense of approximately \$207,000 for the year ended December 31, 2022.

As of December 31, 2022, there were 7,456,500 fully vested options outstanding with a weighted average exercise price of \$0.0518 per share. There were no non-vested options outstanding.

A summary of the Company's stock option plan and changes during the year ended December 31, 2022 is as follows:

	<u>Number of Options</u>	<u>Weighted average exercise price</u>
Balance - beginning of the year	-	\$ -
Granted	7,596,500	0.0518
Exercised	-	-
Cancelled	-	-
Balance - end of the year	<u>7,296,500</u>	<u>\$ 0.0518</u>

The aggregate intrinsic value of vested share options (the market value less the exercise price) at December 31, 2022 was zero.

NOTE 13 - FINANCIAL INSTRUMENTS

(a) Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its obligations associated with financial liabilities. The Company relies on cash flows generated from operations, as well as injections of capital through the issuance of the Company's capital stock to settle its liabilities when they become due.

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 13 - FINANCIAL INSTRUMENTS, continued

(b) Interest Rate Risk The Company is not exposed to significant interest rate risk due to the short-term maturity of its monetary current assets and current liabilities.

NOTE 14 - GENERAL AND ADMINISTRATIVE EXPENSES

	Year ended December 31,	
	2022	2021
Salaries	\$ 1,260,685	\$ 1,016,881
Share based compensation	278,804	2,889,567
Professional fees	185,942	225,384
Other	220,222	79,523
Total general and administrative expenses	\$ 1,945,653	\$ 4,211,355

NOTE 15 - IMPAIRMENT OF LONG LIVED ASSETS

In October 2022, the Company elected not to renew patent rights option for US Patent No 8,287,505 Ophthalmic Drop Dispensing Tip Assembly and expensed the \$3,800 cost basis of this option.

In the fourth quarter of 2021 the Company determined that its fixed assets were obsolete and wrote off the undepreciated balance of \$1,958.

In the first quarter 2021, when the Company's new website was placed in service, the remaining unamortized cost of the Company's old website was written off, for a total of \$15,000.

NOTE 16 - INCOME TAXES

The Company recognizes deferred tax assets and liabilities for the tax effects of differences between the financial statements and tax basis of assets and liabilities. A valuation allowance is established to reduce the deferred tax assets if it is more likely than not that a deferred tax asset will not be realized.

The components of income tax provision (benefit) related to continuing operations are as follows at December 31:

	2022	2021
Current	\$ -	\$ -
Deferred	\$ -	\$ -
Total tax provisions	\$ -	\$ -

The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31:

	2022	2021
U.S. Federal statutory income tax rate	(21)%	(21)%
State income tax, net of federal benefit	(4.5)%	(4.5)%
Valuation allowance	25.5%	25.5%
	0.0%	0.0%

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 16 - INCOME TAXES, continued

The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31:

	2022	2021
Deferred tax assets:		
Net operating loss carry forwards	\$ 2,315,403	\$ 1,337,957
Stock based compensation	1,662,526	1,600,548
Other	-	-
Total	3,977,929	2,938,505
Deferred tax liabilities:	-	-
Less: valuation allowance	(3,977,929)	(2,938,505)
Net deferred tax assets	\$ -	\$ -

The change in valuation allowance was (\$1,039,424) and (\$1,158,381) for the years ended December 31, 2022 and 2021, respectively. We have recorded a 100% valuation allowance related to the deferred tax asset for the income from operations.

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible. In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2022 and 2021, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

NOTE 17 - COMMITMENTS AND CONTINGENCIES

(a) Other The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company's financial position or results of operations.

NOTE 18 - CONCENTRATIONS OF CREDIT RISK

(a) Cash The Company maintains its cash in bank deposit accounts, which may, at times, may exceed federally insured limits. The Company had zero and \$416,178 cash balance in excess of FDIC insured limits at December 31, 2022 and 2021.

NOTE 18 - COVID-19 PANDEMIC AND VARIANTS

The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods.

Curative Biotechnology, Inc
Notes to Unaudited Financial Statements

NOTE 19 - SUBSEQUENT EVENTS

(a) Senior Secured Note In the first quarter 2023, the Company and the lender agreed to the seventh through tenth modifications of the Note. The maturity was reset to May 16, 2023; the default and optional redemption rates were reset to 137.5% and the qualified offering, as described, was reset to \$3 million.

(b) Related party short term note payable In March 2023, the Company issued a short-term 90 day demand note carrying an 8% interest rate to an entity, co-owned by two parties related to the Company, in exchange for \$20,000 cash.

(c) Deficiency in Stockholders Equity Subsequent to December 31, 2021 the Company issued 30,000 shares of Series B preferred stock in exchange for \$30,000 in cash.